Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-012461
Filing Date
2018-05-09
Accepted
2018-05-09 16:36:04
Documents
70
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q achv-10q_20180331.htm 10-Q 1319473
2 EX-10.1 achv-ex101_358.htm EX-10.1 48880
3 EX-31.1 achv-ex311_8.htm EX-31.1 9041
4 EX-31.2 achv-ex312_7.htm EX-31.2 9077
5 EX-32.1 achv-ex321_6.htm EX-32.1 4824
6 EX-32.2 achv-ex322_10.htm EX-32.2 4851
  Complete submission text file 0001564590-18-012461.txt   5799897

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT achv-20180331.xml EX-101.INS 1125196
8 XBRL TAXONOMY EXTENSION SCHEMA achv-20180331.xsd EX-101.SCH 55172
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE achv-20180331_cal.xml EX-101.CAL 55373
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE achv-20180331_def.xml EX-101.DEF 230806
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE achv-20180331_lab.xml EX-101.LAB 402805
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE achv-20180331_pre.xml EX-101.PRE 342606
Mailing Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101
Business Address 520 PIKE STREET SUITE 2250 SEATTLE WA 98101 425-686-1500
ACHIEVE LIFE SCIENCES, INC. (Filer) CIK: 0000949858 (see all company filings)

EIN.: 954343413 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 033-80623 | Film No.: 18818875
SIC: 2835 In Vitro & In Vivo Diagnostic Substances